Adults aged 40 years or older who have moderate-to-severe plaque psoriasis, may qualify for this clinical research trial and receive either investigational oral treatment (active study drug) or comparator medication.

Eligible participants must have plaque psoriasis covering 10% or more of the total BSA (body surface area), with at least 1 of the following cardiovascular risk factors: current cigarette smoker (vaping does not qualify); diagnosis of hypertension or dyslipidemia; use of blood pressure-lowering or lipid-lowering medications; type 1 or type 2 diabetes; have had heart surgery, cardiac arrest, or stroke; obesity (body mass index ≥ 30 kg/m2); OR family history of heart attacks in a relative younger than 55 or a female immediate family member younger than 65.

Participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. Individuals will be asked to visit the study centre about 14 times over a period of about 5 years (272 weeks).

For more detailed information about this clinical trial, please visit:

Study Details | NCT07116967 | Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) | ClinicalTrials.gov

Principal Investigator
A/Prof Peter Foley

Sub Investigators

Study Coordinator
Keri Nemeth
Phone Number: 03 9623 9425
Email: [email protected]